Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive

Jasper Therapeutics, Inc.

2024-FY EPS reported -$4.89

Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.
BEACON study in CSU: multiple dosing regimens ≥120mg showed >25-point UAS7 improvement; Phase 2b expected H2 2025.
SPOTLIGHT study in CIndU: 14 of 15 patients (93%) achieved clinical response; 83% complete response in 120mg cohort.
First patient dosed in ETESIAN asthma study; initial data expected H2 2025.
Open-label extension study commenced; initial data from ~30 patients expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.